Health Logic Interactive Letter to Shareholders
News provided by
Share this article
Health Logic Interactive Inc. (
Health Logic or the
Dear Shareholders of Health Logic,
This is our first letter to the shareholders of Health Logic Interactive Inc. As your CEO, I intend to communicate to you at least quarterly with respect to the state of our business, our significant milestones and achievements, our challenges, our goals, and any new material additions to our organization.
I am extremely excited about our plans to integrate our innovative point-of-care (POC), lab-on-chip (LoC), digital diagnostic technology for Chronic Kidney Disease (CKD) with our digital platform strategy to provide risk analysis, disease education materials, and hold key patient data. Our goal and expectation is for all of this to be possible within the capabilities of your smartphone.
Health Logic Interactive Letter to Shareholders
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Manitoba doctors develop cutting-edge mobile kidney disease detector
winnipegfreepress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from winnipegfreepress.com Daily Mail and Mail on Sunday newspapers.
Health Logic Interactive is Pleased to Announce the Appointment of Experienced MedTech Executive as CEO
News provided by
Share this article
Health Logic Interactive Inc. (
Health Logic or the
Company ) (NEX: CHIP), is pleased to announce the hiring of Mr. David Barthel, as the Chief Executive Officer for Health Logic.
Mr. Barthel is an experienced executive leader in the medical device space with a successful track record.
Mr. Barthel founded The SmartPill and led the company as CEO & President until its acquisition by medical device giant, Medtronic (Nasdaq:MDT). Mr. Barthel successfully took The SmartPill company from its initial patent through the entire product development process, including raising over $70 million USD in multiple funding rounds. Mr. Barthel led his team through multiple clinical trials, manufacturing, FDA approval, and successful insurance reimbursement. After the acquisition by Medtronic, Mr. Barthel joined the company as Area Vice President, GIH